Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital
Read more
Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
Read more
Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
Click Here
Predictive Oncology Accepting New Applications for ACE Program
Click Here
Predictive Oncology highlights a recent successful project in partnership with the University of Michigan
Click Here
Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital
Read more
Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
Read more
Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
Click Here
Predictive Oncology Accepting New Applications for ACE Program
Click Here
Predictive Oncology highlights a recent successful project in partnership with the University of Michigan
Click Here
Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital
Read more
Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
Read more
Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
Click Here
Predictive Oncology Accepting New Applications for ACE Program
Click Here
Predictive Oncology highlights a recent successful project in partnership with the University of Michigan
Click Here

Proactive interviews Predictive Oncology about partnering with Cancer Research Horizons to leverage AI for new cancer drugs

Dominic Pollard of Cancer Research Horizons and Dr. Pamela Bush of Predictive Oncology discuss the potential impact of their collaboration and how it can advance cancer drug development. This alliance between the world’s largest private funder of cancer research, with 11 marketed drugs and 150 active licenses, and the incorporation of our AI-driven, machine-learning PEDAL platform with access to an extensive biobank of tumor-specific samples, represents a promising win for patients, not just in the UK or US, but worldwide.  

Click here to view the interview.

Related Content: